TherapeuticsMD Inc. [NASDAQ: TXMD] price plunged by -4.73 percent to reach at -$0.08. The company report on February 24, 2021 that TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021.
-Executive Management to Host Conference Call on March 2, 2021 at 8:30 a.m. ET-.
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced that it will report its fourth quarter 2020 financial results on Tuesday, March 2, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
A sum of 17057151 shares traded at recent session while its average daily volume was at 11.39M shares. TherapeuticsMD Inc. shares reached a high of $1.70 and dropped to a low of $1.46 until finishing in the latest session at $1.61.
Guru’s Opinion on TherapeuticsMD Inc. [TXMD]:
Jefferies have made an estimate for TherapeuticsMD Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 07, 2020. The new note on the price target was released on May 19, 2020, representing the official price target for TherapeuticsMD Inc. stock.
The Average True Range (ATR) for TherapeuticsMD Inc. is set at 0.22, with the Price to Sales ratio for TXMD stock in the period of the last 12 months amounting to 10.61.
TXMD Stock Performance Analysis:
TherapeuticsMD Inc. [TXMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.44. With this latest performance, TXMD shares gained by 7.33% in over the last four-week period, additionally plugging by 3.87% over the last 6 months – not to mention a drop of -15.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TXMD stock in for the last two-week period is set at 45.13, with the RSI for the last a single of trading hit 38.76, and the three-weeks RSI is set at 48.42 for TherapeuticsMD Inc. [TXMD]. The present Moving Average for the last 50 days of trading for this stock 1.5106, while it was recorded at 1.7340 for the last single week of trading, and 1.4609 for the last 200 days.
Insight into TherapeuticsMD Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and TherapeuticsMD Inc. [TXMD] shares currently have an operating margin of -304.56 and a Gross Margin at +86.01. TherapeuticsMD Inc.’s Net Margin is presently recorded at -354.80.
Return on Total Capital for TXMD is now -78.47, given the latest momentum, and Return on Invested Capital for the company is -91.77. Return on Equity for this stock declined to -330.09, with Return on Assets sitting at -73.71. When it comes to the capital structure of this company, TherapeuticsMD Inc. [TXMD] has a Total Debt to Total Equity ratio set at 2,231.05. Additionally, TXMD Total Debt to Total Capital is recorded at 95.71, with Total Debt to Total Assets ending up at 77.18. Long-Term Debt to Equity for the company is recorded at 2,214.73, with the Long-Term Debt to Total Capital now at 95.01.
Reflecting on the efficiency of the workforce at the company, TherapeuticsMD Inc. [TXMD] managed to generate an average of -$506,164 per employee. Receivables Turnover for the company is 2.80 with a Total Asset Turnover recorded at a value of 0.21.TherapeuticsMD Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.60.
TXMD Stock EPS
With the latest financial reports released by the company, TherapeuticsMD Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.19/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TXMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TherapeuticsMD Inc. go to 17.60%.
TherapeuticsMD Inc. [TXMD] Insider Position Details
There are presently around $259 million, or 44.90% of TXMD stock, in the hands of institutional investors. The top three institutional holders of TXMD stocks are: BLACKROCK INC. with ownership of 21,419,273, which is approximately 14.593% of the company’s market cap and around 11.22% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 18,869,212 shares of the stock with an approximate value of $30.38 million in TXMD stocks shares; and FMR LLC, currently with $22.73 million in TXMD stock with ownership of nearly -1.354% of the company’s market capitalization.
Positions in TherapeuticsMD Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 74 institutional holders increased their position in TherapeuticsMD Inc. [NASDAQ:TXMD] by around 31,068,358 shares. Additionally, 52 investors decreased positions by around 27,947,690 shares, while 45 investors held positions by with 101,672,977 shares. The mentioned changes placed institutional holdings at 160,689,025 shares, according to the latest SEC report filing. TXMD stock had 29 new institutional investments in for a total of 12,080,894 shares, while 14 institutional investors sold positions of 2,712,528 shares during the same period.